pharmexec.com /1 week ago

<![CDATA[Moderna Lays Out Oncology-Driven Growth Plan at 2026 Analyst Day]]>

Read source
newswire.com /2 weeks ago

Moderna Reports Third Quarter 2026 Financial Results and Provides Business Updates

Reports third quarter revenue of $1.3 billion, GAAP net income of $0.2 billion and GAAP diluted EPS of $0.38Increases 2026 expected revenue growth to 15%-25%, exceeding the previou...

Read source
pharmexec.com /1 week ago

<![CDATA[Pharmaceutical Executive Daily: Moderna Outlines Growth Plan at 2026 Analyst Day]]>

Read source
seekingalpha.com /3 weeks ago

Moderna, Inc. (MRNA) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress - Slideshow

Read source
newswire.com /4 weeks ago

Moderna Named a Top Employer by Science for Twelfth Consecutive Year

Read source
newswire.com /2 weeks ago

Moderna Advances Investigational Bundibugyo Ebolavirus Vaccine Toward Phase 2/3 Study

WHO Technical Advisory Group recommends mRNA-1469 for inclusion in efficacy study following encouraging Phase 1 clinical results

Read source
seekingalpha.com /4 weeks ago

Notable healthcare headlines for the week: Moderna, Roche, and Abbott Laboratories in focus

Read source
cafepharma.com /4 weeks ago

Moderna’s Cancer Vaccine: A Medical Breakthrough, a Wall Street Meltdown, and a New Era in Cancer Treatment

Moderna’s Cancer Vaccine: A Medical Breakthrough, a Wall Street Meltdown, and a New Era in Cancer Treatment Anonymous (not verified) Sat, 10/24/2026 - 13:17 pharmagather...

Read source
biopharmadive.com /1 month ago

This week in charts: Moderna’s massive stock run

The latest installment in BioPharma Dive’s data visualization-focused series includes a look at Moderna’s meteoric rise in 2026 and a sudden deal surge from Roche.

Read source
newswire.com /1 month ago

Moderna Adds Chief Operating Officer Role as Company Expands into Oncology

Juan Andres to Return to Moderna as Chief Operating OfficerJerh Collins to Retire Following Four Years of Leadership at Moderna

Read source
marketwatch.com /1 month ago

Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.

Moderna is one of the hottest stocks of the year because of its custom cancer treatment. Full Phase 3 data are set to be revealed this weekend.

Read source
cafepharma.com /4 weeks ago

The Merck/Moderna Results

The Merck/Moderna Results Anonymous (not verified) Fri, 10/23/2026 - 13:17 pharmagather item url The Merck/Moderna Results pharmagather...

Read source
newswire.com /2 weeks ago

Santé Canada autorise deux vaccins à ARNm de Moderna : un vaccin contre la grippe et un vaccin combiné contre la grippe...

Le Canada est le premier pays à autoriser à la fois le vaccin à ARNm de Moderna contre la grippe saisonnière, mFLUSIVA®, et son vaccin combiné contre la grippe et la COVID-19, mCOF...

Read source
fool.com /1 week ago

BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027

Five years after their pandemic-era success, BioNTech and Moderna are racing to transform promising medical breakthroughs into sustainable businesses.

Read source
fool.com /1 week ago

Moderna: 3 Key Takeaways for Long-Term Investors

Its proprietary software is built into the cancer drug itself, creating a front-end design moat that rivals may struggle to replicate.

Read source
asia.nikkei.com /1 month ago

Moderna CEO eyes China partnerships despite geopolitical tensions

Read source
seekingalpha.com /1 month ago

Moderna: Sell The Cancer Vaccine Hype

Read source
law360.com /1 month ago

Northwestern's IP License With Feds Doesn't Protect Moderna

Moderna Inc. has lost its attempt to escape Northwestern University's patent infringement suit over COVID-19 vaccinations by citing the university's patent licensing agreement with...

Read source
fool.com /1 month ago

Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.

It was a head-turning headline. Here's why the market was buzzing.

Read source
newswire.com /2 weeks ago

Health Canada Authorizes Moderna's mRNA Influenza and Combination Influenza and COVID-19 Vaccines

Canada becomes the first country to authorize both Moderna's mRNA seasonal influenza vaccine, mFLUSIVA®, and combination influenza and COVID-19 vaccine, mCOFLU®

Read source
seekingalpha.com /4 weeks ago

Moderna: Why Positive Phase 3 Results Weren't Enough

Read source
litefinance.org /1 week ago

Moderna (MRNA) Stock Forecast & Predictions for 2026, 2027, 2028–2030 and Beyond

Moderna (#MRNA) is a biotechnology company that has gained recognition for its innovative mRNA technology and its role in the development of a vaccine for the novel coronavirus dis...

Read source
biopharmadive.com /4 weeks ago

Moderna, Merck shares fall on eagerly anticipated cancer vaccine results

A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study that met Wall Street expectations but triggered a “sel...

Read source
investing.com /4 weeks ago

Moderna sheds about $24 billion as cancer vaccine data triggers ’sell-the-news’ retreat

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.